Chiesi France company information, Employees & Contact Information

PANTHERx® Rare Selected by Chiesi for the Distribution of MYCAPSSA® PR Newswire

Arbor Bio in $2B+ deal with Chiesi for gene editing therapies BioWorld MedTech

Idebenone Accepted by FDA for Priority Review for Leber Hereditary Optic Neuropathy (LHON) GlobeNewswire

FDA grants priority review for Chiesi's LHON therapeutic Eyes On Eyecare

Chiesi Global Rare Diseases Awards Research Grants to Advance Innovation in Lysosomal Diseases Business Wire

Chiesi unveils €430M investment to revitalize Italian production site for inhaler, biologics manufacturing Fierce Pharma

Rare disease research boost for lysosomal scientists backed by Chiesi Euractiv

Chiesi Group partners Arbor on gene editing programmes Pharmaceutical Technology

Italy's Chiesi Group plans acquisitions to boost sales to 6 billion euros by 2030 Reuters

Italy's Chiesi invests €430M in facility for respiratory therapies FirstWord Pharma

chiesi group opens healthcare innovation regeneration in parma, italy Designboom

Touring Chiesi's vision for the future at the new Biotech Centre of Excellence pharmaphorum

Chiesi Global Rare Diseases Announces Multiple Presentations at 21st Annual WORLDSymposium™ Research Meeting PR Newswire

Chiesi Group and Arbor Biotechnologies Announce a Global GlobeNewswire

Health Canada approves Chiesi’s MYALEPTA for lipodystrophy Pharmaceutical Technology

JPM23: Chiesi gets jump-start on JPM buzz with $1.48B Amryt buyout Fierce Pharma

Chiesi Global Rare Diseases and Protalix BioTherapeutics Announce Validation of Variation Submission by European Medicines Agency for pegunigalsidase alfa PR Newswire

Chiesi Global Rare Diseases Announces Publication of Results from Phase 3 BRIGHT Study of ELFABRIO® (pegunigalsidase alfa-iwxj) in Fabry Disease PR Newswire

Chiesi Global Rare Diseases Announces FDA Approval of Lamzede®(velmanase alfa-tycv) for Alpha-Mannosidosis PR Newswire

Chiesi Global Rare Diseases and Protalix BioTherapeutics Announce FDA Approval of ELFABRIO® (pegunigalsidase alfa-iwxj) for the Treatment of Fabry Disease PR Newswire

Chiesi gets FDA high five for enzyme replacement therapy Lamzede Fierce Pharma

NICE announces UK approval of idebenone for treatment of Leber hereditary optic neuropathy Ophthalmology Times Europe

Chiesi Farmaceutici Headquarters Arup

Chiesi Farmaceutici S.p.A. to Acquire Amryt Pharma Plc GlobeNewswire

FDA Approves Topical Gel Filsuvez for Epidermolysis Bullosa Dermatology Times

Inside the journey of Giuseppe Accogli: From med-tech veteran to Chiesi Group CEO Innovation News Network

Chiesi: Industry-leading respiratory health, rare diseases, and speciality care solutions Innovation News Network

Chiesi Farmaceutici agrees to buy Amryt Pharma for $1.48bn Pharmaceutical Technology

FDA approves Filsuvez to treat dystrophic and junctional EB Epidermolysis Bullosa News

Chiesi Global Rare Diseases Recognizes Rare Disease Day Highlighting Importance of Staying Connected for Information and Support PR Newswire

Chiesi Announces Plans To Build New Manufacturing Plant In Italy Pharmaceutical Online

Chiesi Global Rare Diseases Announces Health Canada GlobeNewswire

Protalix, Chiesi win US go-ahead for Elfabrio in Fabry disease BioWorld MedTech

Chiesi’s $1.25B Amryt Buy Pays Off with FDA Approval of Filsuvez BioSpace

Chiesi Global Rare Diseases Announces FDA Approval of FERRIPROX® (deferiprone) for Treatment of Transfusional Iron Overload due to Sickle Cell Disease PR Newswire

Chiesi Group announces performance growth in 2020 GlobeNewswire

Protalix BioTherapeutics Stock: FDA Approval For Elfabrio To Drive Profitability (NYSE:PLX) Seeking Alpha

Chiesi adds US rights to Fabry disease drug in Protalix deal BioPharma Dive

Ferriprox Twice-a-Day Tablet Dosing Approved for Transfusional Iron Overload Due to Thalassemia Syndromes Medical Professionals Reference

Moderna inks R&D agreements with Vertex and Chiesi PMLiVE

Smith Anderson Advises Chiesi in Agreement to Acquire Three Cardiovascular Hospital Products for up to $792 Million Smith Anderson

Chiesi Farmaceutici and Cornerstone Therapeutics Announce Agreement for a Merger Transaction in Which Chiesi Will Acquire 100 Percent Ownership of Cornerstone for $9.50 Per Share in Cash PR Newswire

Appeal dismissed: patent infringement claim survives strike out Simmons & Simmons